Promising lymphoma combo trial pulled before starting
NCT ID NCT07030699
First seen Jan 05, 2026 · Last updated May 14, 2026 · Updated 23 times
Summary
This study was designed to see if a new combination of three drugs—epcoritamab, lenalidomide, and tafasitamab—could safely and effectively treat people with a type of blood cancer called diffuse large B-cell lymphoma that had come back or stopped responding to treatment. It was planned for about 0 participants, but the study was withdrawn before any patients were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.